Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000947871-26-000500
Filing Date
2026-05-06
Accepted
2026-05-06 17:48:19
Documents
2
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 16912
2 JOINT FILING AGREEMENT ss6292321_ex9901.htm EX-99.1 5321
  Complete submission text file 0000947871-26-000500.txt   23962
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

EIN.: 133976876 | State of Incorp.: DE
Type: SCHEDULE 13D/A

Mailing Address 830 WINTER STREET WALTHAM MA 02451
Business Address 830 WINTER STREET WALTHAM MA 02451 781-999-0232
Q32 Bio Inc. (Subject) CIK: 0001661998 (see all company filings)

EIN.: 473468154 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-90433 | Film No.: 26949987
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)